Slide 1: Cingulate Inc.
Cingulate Inc. Developing Next-Generation Therapeutics to Address Unmet Needs in Billion Dollar Markets 40 2023 CING-US-127-0724
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than stat
Slide 3: Current Medication Options Do Not Deliver Acceptable Outcomes
[ Boosters Tolerability Efficacy Cost (s) Current Medication Options Do Not Deliver Acceptable Outcomes for Patients, Providers, and Payors Onset / Duration CING-US-127-0724 Abuse / Diversion
Slide 4: Cingulate's PTR Platform Could Solve These Issues
WA Efficacy vo Boosters Cost (s) v Cingulate’s PTR™ Platform could Tolerability Solve these issues affecting Millions of Patients A v Onset / Duration Abuse / Diversion CING-US-127-0724
Slide 5: Why Cingulate
Why Cingulate (Nasdaq: CING) Completed & Near-Term Catalysts (CTx-1301) Multiple Long-Term Revenue Streams Commercialization Strategy & Execution in Place Impressive Phase 3 Adult Effect Size Phase 3 Pediatric & Adolescent Trials Underway ° * On Target Completion and Data in 1H’24 ° Planned NDA Subm
Slide 6: Multiple Near-Term Milestones Expected and Achieved
Multiple Near-Term Milestones Expected and Achieved ADHD CTx-1301 CTx-1302 Anxiety CTx-2103 PTR™ Platform “CINGULATE: 1H 2023 3Q 2023 > 4Q23/1H 24 > A cTx-1301 Phase 1 Food Effect Clinical Data > VCTx-1301 Adult Onset / Duration Efficacy Trial > SCTx-2103 Formulation Study Report > V Expand Manufact
Slide 7: Next-Generation Medications in Billion-Dollar Markets
Next-Generation Medications in Billion-Dollar Markets Precision Timed Release™ (PTR™) Platform Unlocks the Possibility for ‘True’ Once-daily, Multi-dose Tablets innediate — Film Coat See the PTR™ Platform in Action @ Cingulate.com Ox Gr “Symphony Data, 12-monthe rolling through Jun 2022 CINGULATE’ C
Slide 8: PTR Facilitates a Potential Pipeline Addressing Multiple Indications
PTR Facilitates a Potential Pipeline Addressing Multiple Indications * ADHD (ctx-1301, 1302) * Anxiety (cTx-2103) Insomnia Depression Bipolar Disorder Parkinson's Disease Cardiovascular Disorders Xerostomia (dry mouth) Migraine Hypothyroidism Oral Oncology Medicines Psychosis Alzheimer’s Disease Pai
Slide 9: The Cingulate Solution for ADHD Patients & Providers
The Cingulate Solution for ADHD Patients & Providers MEMASTERY” YSACCOMPLISH® ‘ CTx-1301 CTx-1302 CING-US-127-0724
Slide 10: Targeting Treatment of ADHD - $20+Bn US Market Opportunity
Targeting Treatment of ADHD - $20+Bn US Market Opportunity Frequently diagnosed, chronic pattern interfering with functioning / development 17 Million US ADHD Patients Societal Impact of ADHD 11M Adults & 6M Children/Adolescents Stimulants 90% of Non-Stimulants: Estimated annual incremental costs of
Slide 11: ADHD Market Currently Dominated by Stimulant Products
ADHD Market Currently Dominated by 4 Stimulant Products Major Unmet Medical Needs Persist D BRANDS ATTRIBUTES? INMET NEEDS1 Fast Onset of Duration Action Entir Minimize ( t) (0 min Day Effic Rebound | Avoid Booster x x Vyvanse® 2007 2 hours 12 hours x Dats Not Available ‘Adderall® XR 2001 ee 10 Ye h
Slide 12: What Has CTx-1301 Clinical Data Shown Us?
What Has CTx-1301 Clinical Data Shown Us? Impressive Effect Size in the Treatment of ADHD ¢ Ideal product profile with 3 precisely timed, ratioed, and styled releases of medication ¢ Phase 3 adult study * Psych Congress finalist at poster award reception ° Effect size 2, 3, 5 x greater* than availab
Slide 13: Why is Effect Size Important?
Why is Effect Size Important? * Conveys Clinical Significance versus Statistical Significance ¢ Not Reliant on Sample Size ¢ Allows for Comparison Across Trials * p-value is not translational McGough JJ, Faraone SV. Estimating the size of treatment effects: moving beyond p values. Psychiatry (Edgmon
Slide 14: One Product Designed to Overcome All Unmet Needs
One Product Designed to Overcome All Unmet Needs Entire Active-Day Efficacy, Stop the Crash & Rebound, Eliminate the Booster Dose 7am Noon 3pm —O CTx-1301 6.25-mg ~~ Focalin XR 5-mg +— Extended Efficacy Fast Acting Duration (S 30 min) (CTx-1301 (MPH) 30 mins Up to 16 hours v CTx-1302 (LAMP) 30 mins
Slide 15: PERMP CTx-1301 & Placebo Adult Laboratory Classroom
PERMP CTx-1301 & Placebo Adult Laboratory Classroom 40 Change from Baseline 15 10 cin CTx-1301 (N=11) Data on file, Cingulate Inc. 1301-022 NCT 05631626 m Placebo (N=10) 353 32.4 288 aa 278 if 247 214 19.2 18.6. 8.7 19.6 18.3 16.7 144 naa 02 qa 72 72 Yad 30MINUTES 1 HOUR 3HOURS GHOURS. © SHOURS.-«12
Slide 16: PERMP Effect Size over hours
PERMP Effect Size over 16 hours A Meta-Analysis conducted by Faraone and Glatt (Clin Psych 71:6 3.00 June 2010) using 11 published studies with long-acting stimulants in adults demonstrated the Average Effect Size to be 0.73 (approximate range 0.5 to 0.9). w 2.50 N CTx-1301 Average Effect Size: 1.79
Slide 17: AISRS: CTx-1301 Delivered Ongoing Reduction in ADHD Severity
AISRS: CTx-1301 Delivered Ongoing Reduction in ADHD Severity 37.0 g a8 —— PLACEBO (N=10) —==CTX-1301 (N=11) é 30.7, a i 27.0 w Mean Difference: a -13.1 wy p<0.001 8 22.0 a 16.4 48.2 n | a & 17.0 < \ ' \ ' ) 12.0 Dose Optimization Phase Randomized, Placebo-Controlled Phase (All Patients Treated with
Slide 18: Adult ADHD Investigator Symptom Rating Scale
Adult ADHD Investigator Symptom Rating Scale CTx-1301 AISRS Effect Size (Cohen's d) All subjects treated with CTx-1301 Mean Starting jean Baseline Mean Baseline 7 (pre-dose) 8 LS Mean CFB (Visit 7 to Visit ) Effect Size (Cohen's d) (CT-1301-022 32.7 (5.06) 16.4 (4.86) 18.2 (7.59) 1.9 41.66 Placebo 3
Slide 19: ADHD Effect Size Comparison
ADHD Effect Size Comparison* Peak Effect Size** Percentiles ADHD Products & Candidate (Cohen's d) p-value (Cohen's d) CTx-1301*** 5.45 @ 1 week <0.001 Concerta ® 0.42 @ 6 weeks <0.001 ~69% Vyvanse ® 0.94 @ 10 weeks <0.001 ~84% Azstarys ® 0.49 @ 4 weeks 0.003 ~b69% Adderall® XR 0.80 @ 4 weeks <0.001
Slide 20: CTx-1301 Demonstrated Significantly Lower Adverse Events
CTx-1301 Demonstrated Significantly Lower Adverse Events 28.6% reduction in TEAE’s related to CTx-1301 versus Focalin XR (14.3% difference) Focalin XR CTx-1301 Focalin XR CTx-1301 All All 5mg 6.25 mg 40 mg 50 mg CTx-1301 Focalin XR (n=41) (n=39) (n=43) (n=42) (n=42) (n=44) Treatment Emergent Adverse
Slide 21: The ADHD Medication Providing Daily Durability
The ADHD Medication Providing Daily Durability Precision Timed Release™ (PTR™) Platform Unlocks the Possibility for ‘True’ Once-daily, Multi-dose Tablets $20+ Fast Onset : Eliminate Need for Billion’ ‘ "Booster/Recovery’ Meds US ADHD Eliminate Market Rebound/Crash Dominated by \ i Avoid ‘Wear-off' }
Slide 22: CTx-1301 Clinical and Regulatory Timeline
s YESMASTERY ° CTx-1301 Clinical and Regulatory Timeline 2022 2023 2024 CLINICAL PHASE 3 Pediatric / Adolescent Fixed-Dose, PHASE 3 Placebo-Controlled Study PHASE | Adult Dose- n~325 Food Optimization Efficac Effect ahd Safety Study ot PHASE 3 Clint bes Study Evaluate Onset and ERASE S gram n=26 Dur
Slide 23: The Cingulate Solution for Anxiety Patients & Providers
The Cingulate Solution for Anxiety Patients & Providers CING-US-127-0724
Slide 24: CTx-2103 — Buspirone HCl for the Treatment of Anxiety
CTx-2103 — Buspirone HCl for the Treatment of Anxiety Next-Generation Buspirone designed to Improve Patient Outcomes Three Times a Day versus Single Dose Buspirone 10 mg- Immediate Release ° 5 ” sours » ‘Treatment D: A single tablet releasing 10 mg buspirone HCL (commercially available) immediately
Slide 25: Commercialization Strategy
Commercialization Strategy Best in Class Market Preparation and Execution CINGULATE’ int\degene’
Slide 26: Traditional Pharmaceutical Commercialization Is Increasingly Challenged
Traditional Pharmaceutical Commercialization Is Increasingly Challenged 1in5 products reach peak U.S. sales of $1B* 62% 50% of products launched in the last of products fail to reach peak U.S. 15 years have underperformed sales of $250M* pre-launch forecasts! Furthermore, a recent McKinsey study? in
Slide 27: Cingulate & Indegene Integrated GTM Solution
Cingulate & Indegene Integrated GTM Solution Customer focused, integrated solutions model allows for more effective commercialization and higher revenue generation than traditional commercial options Patient Services “CINGULATE: ————— Grevetecom © 2023 Cingulate Inc. “Consumer defined as Patient, Ca
Slide 28: Value Maximizing Commercial Model
Value Maximizing Commercial Model Leverage Al and ML to build a commercial model based on the best mix to drive revenue * Hundreds of reps target inaccessible HCPs (60-75%) * Expensive, inefficient and ineffective * Reps and individual channels are not integrated 71 Traditional Model * Proprietary A
Slide 29: Why Cingulate
Why Cingulate (Nasdaq: CING) @ Near and Long-Term Future Revenue Streams @ CING is Building Multiple Assets that Solve Real Problems Commercialization is Built and Ready for Scale CINGULATE: ———— Grevetecom © 2023 Cingulate Ine.
Slide 30: Thank You
CINGULATE’ Thank You